#United States #Transpara #Colorado Springs #ScreenPoint Medical #AI Breast Imaging

Transpara® Showcases Innovative AI Technologies at SBI 2025

ScreenPoint Medical is set to present its flagship product, Transpara®, at the 2025 Society of Breast Imaging (SBI) Symposium, taking place from April 24 to April 27, 2025, in Colorado Springs. This event will spotlight Transpara®'s latest advancements in breast cancer detection, reinforcing its position as the most clinically validated AI solution available in the market.

Enhancing Radiology with Advanced Features

The highlight of ScreenPoint's showcase will be the introduction of Transpara 2.1, an updated algorithm that promises to elevate breast cancer detection capabilities significantly. Key to this upgrade is the incorporation of breast density assessment, aligning with BI-RADS guidelines, and a groundbreaking temporal comparison feature that allows for the evaluation of suspicious areas across multiple prior mammograms—up to three exams over a six-year span.

“This innovative temporal comparison will mark a first in the industry and facilitate more informed decisions by professionals,” stated Professor Nico Karssemeijer, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical.

The study results aiming to validate these features will be shared through numerous presentations at the symposium, emphasizing their clinical utility in everyday radiology practice.

Demonstrating Clinical Efficacy

One of the pivotal talks at SBI will be led by Dr. Alejandro Rodriguez Ruiz, focusing on the validation of Transpara Risk, an image-based AI model designed for breast cancer risk assessment in mammography screening. This study underscores its capability to support personalized screening by identifying high-risk women suitable for additional imaging.

Moreover, a separate presentation will detail the successful multi-site validation of an AI system for cancer detection in abbreviated breast MRI. Participants can look forward to insights regarding the tool’s efficacy in identifying normal exams accurately, underscoring its potential to assist radiologists in making precise decisions in mammography workflows.

Practical AI Integration in Radiology

Dr. Rachel F. Brem, another key speaker, will discuss practical strategies for integrating AI into breast imaging practices, underlining the necessity for radiologists to be well-versed in how, when, and why to incorporate AI tools to enhance their diagnostic capabilities.

Transpara remains the only breast AI algorithm extensively evaluated in large-scale, real-world screening programs, with over 35 peer-reviewed publications validating its performance. Notably, results from the MASAI trial reported a remarkable increase of 29% in cancer detection rates and a 44% decrease in the workload burden for radiologists, showcasing Transpara’s impact on improving clinical workflows and outcomes.

About ScreenPoint Medical

Committed to translating advanced machine learning research into practical applications, ScreenPoint Medical focuses on enhancing radiologists' decision-making processes and efficiency in breast cancer detection and risk assessment. The team's dedication to continuous improvement through user feedback from global radiologists has made Transpara a trusted tool in breast imaging.

To discover more about their cutting-edge solutions, visit their official website: ScreenPoint Medical.

Transpara is set to revolutionize breast imaging once again at SBI 2025, demonstrating the power of AI in augmenting human clinical expertise.